O n Friday, H.C. Wainwright maintained a Buy rating on Astria Therapeutics stock, with a price target of $16.00. The firm's decision follows Astria's announcement of the initiation of a Phase 1a ...

Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "With the ALPHA-ORBIT Phase 3 trial of navenibart, we are enabling the potential for HAE patients to break free from the gravity of ...

Astria Therapeutics (NASDAQ:ATXS – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Monday, March 3rd.Analysts expect the company to announce ...

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Astria Therapeutics (ATXS – Research Report) and uniQure (QURE – Research Report) with bullish ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of ATXS opened at $5.34 on Friday. Astria Therapeutics has a one year low of $5.29 and a one year high of $14.04. The stock has a 50-day moving average price of $6.76 and a 200 day moving ...

Wedbush analyst Richard Anderson maintained a Buy rating on Astria Therapeutics (ATXS – Research Report) today and set a price target of $28.00. The company’s shares closed yesterday at $6.47.

BOSTON, April 02, 2025--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases ...

Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company ...